Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mike Ward

London, UK
Mike has been writing, analysing and commenting on the life sciences industry for more than 30 years as a journalist and investment bank analyst. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry's key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year and has appeared on the shortlist for that award on numerous occasions. When not commentating on all things pharma, Mike is engaged actively in pub quizzes, either as a competitor or a compiler. He is also a qualified FA soccer coach.
Set Alert for Articles By Mike Ward

Latest From Mike Ward

Korean Pharma Spawns US Cancer Biotech Startup

Dr. Benjamin R Cowen, COO of ImmunoMet Therapeutics, reveals how the Houston-based startup is developing OXPHOS inhibitors to treat drug resistant and relapse cancers.

Companies StartUps and SMEs

Shanghai Henilus Biotech Has Blockbuster Biologics In Biosimilars Crosshairs

Dr. Cheni Kwok, a business development and strategy consultant, caught up with Scrip’s Mike Ward to outline how Shanghai Henilus Biotech is positioning itself to provide affordable healthcare globally.

Asia Pacific Biosimilars

Producing Monoclonal Antibodies For A Tenth Of The Cost

Dutch antibody technology company BiosanaPharma is offering to make monoclonal antibodies at between 5% and 10% the usual cost of manufacture. Video interview from BIO-Europe Spring.

Biologics Manufacturing

The Future's Bright For Microbiome Investing, Says VC

Seventure Partners’ Eric de la Fortelle explains how the venture capitalist’s €160bn fund will prosper from the increased understanding of human and microbe interactions.

Innovation Financing

vitalityDNA Plans To Keep Healthy People Healthy

vitalityDNA is taking the preventative approach to health care with its personalized health and lifestyle plan offering. The start-up will initially target consumers and then health care companies.

In Vitro Diagnostics StartUps and SMEs

Mitochondrial Medicine Focus Drives NeuroVive Orphan Ambitions

Erik Kinnman, CEO of NeuroVive Pharmaceutical, spoke to Scrip about the company's work in mitochondrial medicine. The company aims to develop orphan drugs to treat rare genetic conditions and seek partners for its NASH and liver cancer projects.

Rare Diseases StartUps and SMEs
See All